Compare Ecolab Inc. (ECL) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Johnson & Johnson — how do they compare? Ecolab Inc. trades at $281.74 (market cap $78.97B), while Johnson & Johnson trades at $256.82 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 7.8× Ecolab Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Johnson & Johnson for 129 Days on average.
| ECL | JNJ | |
|---|---|---|
Market Cap | $78.97B | $618.09B |
Volume | 974,947 | 6,050,983 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $278.43 |
52-Week Low | $245.73 | $186.00 |
Typical Hold Time | 90 Days | 129 Days |
Enterprise Value | $87.75B | $646.37B |
Dividend Yield | 1.04% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $278.10, down 0.97% on the day, with strong analyst support (78% buy ratings) and a $326.38 consensus price target suggesting 17% upside. The stock shows bullish technical signals with support at $275 and resistance at $279. Recent Q2 2026 earnings beat expectations with 9.7% sales growth, while the company maintains dividend aristocrat status with consistent payout increases.
ECL presents a compelling growth story with expanding high-tech and digital segments, though elevated valuation multiples (P/E 37.81) and rising debt from the CoolIT acquisition warrant caution. The essential nature of its hygiene and water management services provides defensive characteristics, while upcoming Q3 earnings on October 27 will be critical for validating growth trajectory.
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
